Cadila Healthcare Ltd.

Cadila Healthcare Ltd.

Cadila Healthcare Ltd.

Overview
Date Founded

1995

Headquarters

Zydus Corporate Park,Scheme No. 63, Survey No. 536,Sarkhej-Gandhinagar Highway,Ahmedabad, Gujarat 382481

Type of Company

Public

Employees (Worldwide)

16.3K

Industries

Pharmaceuticals

Company Description

Cadila Healthcare Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. It offers therapeutic proteins, monoclonal antibodies, and antibody-drug conjugates. It operates through the following geographical segments: India, US, and Others. The company was founded by Ramanbhai B. Patel in 1952 and is headquartered in Ahmedabad, India.

Contact Data
Trying to get in touch with decision makers at Cadila Healthcare Ltd.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Executive Chairman

Joint Managing Director & Executive Director

Chief Financial Officer

Chief Operating Officer

Secretary & Compliance Officer

Strategic Adviser

Board of Directors

Executive Chairman at Cadila Healthcare Ltd.

Founder at AIA Engineering Ltd.

Joint Managing Director & Executive Director at Cadila Healthcare Ltd.

Chairman & Managing Director at Desai Brothers Ltd.

Former President at Ahmedabad Management Association

Partner at Raval & Raval Advocates

Partner at Desai & Diwanji

Chief Operating Officer at Cadila Healthcare Ltd.

Paths to Cadila Healthcare Ltd.
Potential Connections via
Relationship Science
You
Cadila Healthcare Ltd.
Owners & Shareholders
Details Hidden

KMAMC’s portfolio management services include equity and fixed-income solutions. For equities, they offer a special situations value portfolio which seeks to invest in value opportunities and special situations in individual stocks and related instruments which are trading at a discount to their intrinsic value. For fixed-income, the firm seeks to invest in companies with strong fundamentals and cash flow and a mix of PSU and Private Issuer fixed-income instruments. KMAMC invests through their mutual funds in equity funds, fixed-income funds, balanced funds, ETFs and fund of funds.

Details Hidden

ABSLAMC is a long-term, fundamental research-based investor which manages portfolios invested in equity, fixed-income and money-market instruments across regions and sectors. These assets are available via a wide range of financial vehicles including diversified or sector specific equity funds, fund of funds, hybrid and monthly income funds, debt and treasury products and offshore funds. These funds can be actively or passively managed. The firm’s equity fund invests in stocks/equity shares of companies of different market capitalization. Their debt mutual fund invests in a mix of debt investments such as treasury bills, government securities (G-Secs), corporate bonds and other money market instruments of varying maturities that seek to provide investors capital preservation and regular income. ABSLAMC’s hybrid fund invests in a mix of growth oriented equity, capital preserving debt and other assets related instruments, which can vary proportionally over time or remain fixed.

Details Hidden

FTAM-India’s investment philosophy is based on the belief that the analysis of fundamentals is more rewarding in the long-term than technical, even though these can be useful in the short-term. The firm's equity portfolio managers are primarily bottom-up investors. They conduct in-house fundamental research and use quantitative models based on proprietary research to screen the equity market and filter investment opportunities. They complement this research process with company visits and meetings with key management. FTAM-India’s analysts work as a team and meet regularly to discuss investments. Their research is shared on a common platform and investment team members interact with the firm's analysts across the globe.

Recent Transactions
Details Hidden

Windlas Biotech Ltd. purchases Windlas Healthcare Pvt. Ltd. from Cadila Healthcare Ltd.

Details Hidden

Cadila Healthcare Ltd. purchases Zydus Technologies Ltd.

Details Hidden

Cadila Healthcare Ltd. purchases Windlas Healthcare Pvt. Ltd. from Windlas Biotech Ltd.

Transaction Advisors
Investment Advisor

Advised onCadila Healthcare Ltd. purchases German Remedies Ltd.

Advisors & Consultants
Legal Advisor

Partner at Kasowitz Benson Torres LLP

Clients

China Medical System Holdings Limited (“CMS”, together with its subsidiaries, the "Group") is a pharmaceutical services provider based in China, focusing on marketing promotion and sales of prescription drugs to all therapeutic departments in hospitals. The Group was established in 1995, and was listed on AIM in London (ticker: CMSH) in June 2007, the Group was listed on Main Board Market in Hong Kong on 28 September 2010 while it was delisted on AIM at the same time. The Group follows two business models which can be commonly found in the pharmaceutical industry in China, the Direct Academic Orientated Promotion Model and Agency Promotion Model, and with two distinct third party promotion networks, the Direct Academic Orientated Promotion Network (the “Direct Network”) and the Agency Promotion Network (the “Agency Network”), both of which hold leading positions in the Chinese market. On the 3 April 2011, the Group successfully acquired Great Move Enterprise Limited (“Great Move”) and its subsidiaries, the main wholly subsidiary of Great Move is Tianjin Precede Medical Trade Development Co., Ltd.(which has been officially renamed Tianjin Kangzhe Pharmaceutical Technology Development Co., Ltd.on 24 October 2011), which mainly engages in the marketing, promotion and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies via Agency Network in China. After the acquisition, the Group` business model evolved from simply depending on internal marketing and promotion team to promote and sell products directly to physicians (Direct Academic Orientated Promotion Model) to a new integrated development model that incorporates the independent third party sales representatives and distributors to sale and promote products (Agency Promotion Model) in China. On the 31 May 2011, the Group successfully acquired 51% equity interests of Guangming Pharmaceutical Co., Ltd. (which has been officially renamed Guangxi Kangzhe Guangming Pharmaceutical Co., Ltd. on 10 October 2011) via cash investment for capital and stock increase to gain the permanent China market rights of a type of enteral nutrition drug-“Protein Hydrolysate”. The speedy introduction of this product is the result of the combination of the professional academic ability from our Direct Network and the rapid market coverage ability of our Agency Network. We introduce drugs that prove to be competitive and focus on providing marketing, promotion and sales services to specialty pharmaceutical companies by leveraging our successful product selection system and the insights in Chinese pharmaceutical market. As at 31 December 2011, the Direct Network of the Group had close to 1,200 sales, marketing and promotion professionals; the Agency Network had close to 1,000 independent third party sales representatives or distributors and around a hundred of senior regional and marketing managers. The Group`s sales coverage spanned over 14,600 hospitals throughout China, of which almost 8,600 hospitals were covered by the Direct Network and over 7,800 hospitals were covered by the Agency Network. The Group follows a market-oriented product selection strategy and introduces prescription drugs with high growth potential under its Direct Academic Orientated Promotion Model. We formulate appropriate marketing strategies for each drug, leveraging the insights in the Chinese pharmaceutical market, prevailing treatment protocols of physicians, demographic profile of the relevant patient pool in China and potential competitive advantages of drugs. Meanwhile, in order to help drive demand for pharmaceutical products, our professional, stable and experienced marketing, promotion and sales team conducts various physician-oriented academic promotion activities such as one-on-one physician visits, medical symposia and industry conferences, and via our proprietary information management system to keep track of these activities and review operations in a timely manner, enabling us to manage our overall business effectively and efficiently. In addition, the Group also provides other ancillary services needed by pharmaceutical companies to introduce their products to China, including handling product registration, clinical trials, and bidding in collective tender processes. With appropriate product positioning, strategic planning and execution, the Group gained remarkable performance. From 2007 to 2011, the compound annual growth rate (CAGR) of revenue was 42.0%, and the CAGR of net profit achieved 63.7%. We also received a number of recognitions, including the Group was ranked in the list of Forbes “Asia’s Best 200 Enterprises Under a Billion” in 2008 and “Top 100 Enterprises in Shenzhen” in 2009, 2010 and 2011, and we also gained Forbes “China’s Best Up-and-Coming Business” three times in 2010, 2011 and 2012. As a leading China-based pharmaceutical services company, the Group established long-term business partnership with specialty pharmaceutical companies from Germany, Denmark, Ireland, France, Ukraine, Japan and China. We will continuously introduce new products and extend marketing, promotion and sales network to strengthen our leading position in Chinese pharmaceutical service market, and through the professional and quality service to catch opportunities from the enormous growth of Chinese pharmaceutical market and strives to become the preferred partner for overseas and domestic pharmaceutical companies who target at Chinese market.

Medicure, Inc. is a pharmaceutical company, which engages in the research, clinical development, and commercialization of cardiovascular therapeutics. It focuses on the marketing and distribution of its acute care cardiovascular drug, AGGRASTAT; ZYPITAMAG (pitavastatin) tablets and the ReDS device in the United States. The company was founded by Albert D. Friesen on September 15, 1997 and is headquartered in Winnipeg, Canada.

Key Stats and Financials As of 2020
Market Capitalization
$6.42B
Total Enterprise Value
$4.69B
Earnings Per Share
$0.15
EBITDAMargin
18.69%
Enterprise Value / Sales
2.53x
Enterprise Value EBITDAOperating
13.52x
TEVNet Income
30.13x
Debt TEV
0.23x
Three Year Compounded Annual Growth Rate Of Revenue
14.58%
Revenue
$1.85B
Net Profit
$156M
EBITDA
$347M
Total Debt
$1.06B
Total Equity
$1.55B
Investments
Details Hidden

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Suppliers
Ess Dee Aluminium Ltd. Paper Products | Mumbai, India

Ess Dee Aluminium Ltd. is a holding company, which engages in the manufacture of packaging materials for pharmaceutical, food, and fast-moving consumer goods industries. It specializes in cold form blister and child-resistant-blister packaging. The company was founded in 1991 and is headquartered in Mumbai, India.

Ligand Pharmaceuticals, Inc. Medical Support Services | La Jolla, CA

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Borosil Renewables Ltd. Other Raw Materials | Mumbai, India

Borosil Renewables Ltd. engages in the trading and manufacturing of scientific and industrial products, consumer products, and flat glass. It operates through the following segments: Scientificware, Consumerware, Flat Glass, Investments, and Others. The Scientificware segment sells laboratory glassware, scientific ware and pharmacautical packaging. The Consumerware segment manufactures and trades items for domestic use. The Flat Glass segment produces flat glass. The Investments segment involves investment activities. The Other segment comprises of items for industrial use and miscellaneous trading items. The company was founded on December 14, 1962 and is headquartered in Mumbai, India.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Cadila Healthcare Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Cadila Healthcare Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Cadila Healthcare Ltd..